Asset profile

Dolutegravir · Tivicay / Triumeq / Dovato / Juluca (component)

Small molecule

Approvedregulatory verdict

Evidence outlook

Approved — HIV

Regulatory approval supersedes design-level evidence grading — the trials behind approval are preserved below as the drug's evidence history.

track record: Reliable signal

How the evidence outlook works ↗

Upcoming events

(8 total)

Estimated primary-completion dates from ClinicalTrials.gov — registry estimates, never confirmed readout dates; they can move as trials progress.

2026 (2)
November 2026 (1)
Phase 3HIVRecruiting
Est. primary completion 2026-11-30 · NCT04892654 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

December 2026 (1)
Phase 3HIVRecruiting
Est. primary completion 2026-12 · NCT06747507 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2027 (1)
March 2027 (1)
Phase 2HIVRecruiting
Est. primary completion 2027-03-01 · NCT06805656 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2028 (4)
January 2028 (4)
Phase 1/2HIVRecruiting
Est. primary completion 2028-01-31 · NCT02140255 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 1/2TuberculosisNot yet recruiting
Est. primary completion 2028-01-31 · NCT07124559 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Healthy Volunteer, Weight Gain, Metabolic Effects, Integrase Strand Transfer InhibitorsRecruiting
Est. primary completion 2028-01-31 · NCT05652478 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 3HIVRecruiting
Est. primary completion 2028-01-31 · NCT06497465 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2032 (1)
September 2032 (1)
Phase 3HIVRecruiting
Est. primary completion 2032-09-14 · NCT07393659 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

See the full readout calendar ↗

All registered studies

Research

Unlock the complete ClinicalTrials.gov registry

Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.

Competitive landscape

Research

Unlock the competitor landscape

Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.